Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury

@article{Aithal2011CaseDA,
  title={Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury},
  author={G. Aithal and P. Watkins and RJ Andrade and D. Larrey and M. Molokhia and H. Takikawa and C. Hunt and R. Wilke and M. Avigan and N. Kaplowitz and E. Bjornsson and AK Daly},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2011},
  volume={89}
}
Drug‐induced liver injury (DILI) is the most frequent reason cited for the withdrawal of approved drugs from the market and accounts for up to 15% of the cases of acute liver failure. Investigators around the globe have begun to identify and study patients with DILI; several large registries and tissue banks are being established. In order to gain the maximum scientific benefit from these efforts, the definitions and terminology related to the clinical phenotypes of DILI must be harmonized. For… Expand
Translating new knowledge on drug-induced liver injury into clinical practice
TLDR
Advances and results obtained by DILI registries around the world, case characterisations, particularly those relevant to newer definitions in DILi, and the behaviour of chronic liver disease induced by drugs will be updated. Expand
Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice.
TLDR
Risk factors for chronicity, specific phenotypes, and histological features are discussed in this study and prognostic scoring algorithms for the early identification of DILI patients who may go on to develop ALF have been developed. Expand
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury
TLDR
Genome wide association studies taking advantage of large databases of DILI cases included in Registries and Consortia networks have identified several alleles from the major histocompatibility complex system indicating a fundamental role of the adaptive immune system in DILi pathogenesis. Expand
The diagnosis and management of idiosyncratic drug‐induced liver injury
  • Ammar Hassan, R. Fontana
  • Medicine
  • Liver international : official journal of the International Association for the Study of the Liver
  • 2019
TLDR
A number of promising diagnostic, prognostic and mechanistic serum and genetic biomarkers may help improve the understanding of the pathogenesis and treatment of idiosyncratic DILI. Expand
Causality Assessment for Suspected DILI During Clinical Phases of Drug Development
TLDR
A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials, and there is a need for a systematic revision of RUCAM to render it more suitable for the setting of clinical trials and drug development. Expand
The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond.
  • James H. Lewis
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2015
TLDR
Drug-induced liver injury (DILI) remains a leading reason why new compounds are dropped from further study or are the subject of product warnings and regulatory actions, and the quest for a predictive biomarker to replace alanine aminotransferase is ongoing. Expand
An Update on Drug-induced Liver Injury.
  • H. Devarbhavi
  • Medicine
  • Journal of clinical and experimental hepatology
  • 2012
TLDR
An overview of the epidemiology, the patterns of hepatotoxicity, the pathogenesis and associated risk factors besides its clinical management is provided. Expand
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
TLDR
The minimum dataset deemed adequate for causality assessment provides a path forward for standardization of data collection in the setting of DILI and continues to optimize and advance innovative tools necessary for the scientific, pharmaceutical, and regulatory community. Expand
Diagnostic and prognostic assessment of suspected drug‐induced liver injury in clinical practice
  • R. Andrade, M. Robles‐Díaz
  • Medicine
  • Liver international : official journal of the International Association for the Study of the Liver
  • 2019
TLDR
The best diagnostic and prognostic approach of a DILI suspicion is discussed by judiciously choosing and interpreting the standard tests currently used in clinical practice. Expand
Drug-induced liver injury: a safety review
TLDR
Despite the substantial progress made over this century, new approaches using big data analysis to characterize the true incidence of DILI are needed and to categorize the drugs’ hepatotoxic potential. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 98 REFERENCES
Development and validation of a clinical scale for the diagnosis of drug‐induced hepatitis
TLDR
The clinical scale was shown to have a high‐level of validity and inter‐rater reliability as well as a good discriminatory capacity between different levels of probability, suggesting that the scale is suitable for use in clinical practice and may contribute to overcome the difficulties in the process of causality assessment in DILI. Expand
Using controlled clinical trials to learn more about acute drug‐induced liver injury
Drug‐induced liver injury (DILI) is of major interest to hepatologists and clinicians in general, patients, government regulators, and the pharmaceutical industry. Understanding why this form ofExpand
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.
TLDR
Patients with drug-induced hepatocellular jaundice have 11.7% chance of progressing to death or transplantation, and amoxicillin-clavulanate stands out as the most common drug related to DILI. Expand
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.
TLDR
This report summarizes the causes, clinical features, and outcomes from the first 300 patients enrolled in a prospective study to recruit patients with suspected idiosyncratic drug-induced liver injury and create a repository of biological samples for analysis. Expand
Important elements for the diagnosis of drug-induced liver injury.
TLDR
Efforts to promote and include a list of essential diagnostic elements in research articles could increase the quality and clinical utility of published case reports of drug toxicity. Expand
Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase™
TLDR
A unified list that combines drugs incriminated in well vetted or adjudicated DILI cases from many recognized sources and drugs that have been subjected to serious regulatory actions due to hepatotoxicity is developed to supplement the drug list with data on reporting frequencies of liver events in the WHO individual case safety report database (VigiBase™). Expand
Outcome of acute idiosyncratic drug‐induced liver injury: Long‐term follow‐up in a hepatotoxicity registry
TLDR
Patients with cholestatic/mixed injury were more prone to chronicity than patients with hepatocellular injury, and cardiovascular and central nervous system drugs are the main groups leading to chronic liver damage. Expand
Histological patterns in drug-induced liver disease
The diagnosis of drug-induced liver injury (DILI) is a challenging problem, often confounded by incomplete clinical information and the difficulty of eliciting exposure to herbal products,Expand
Comparison of two clinical scales for causality assessment in hepatotoxicity
TLDR
The CIOMS scale showed better discriminative power and produced assessments closer to those of specialists, while the M&V scale was poor in reactions with long latency periods, evolution to chronicity after withdrawal, or death. Expand
Drug-induced liver injury.
TLDR
It is hoped that this chapter will shed light on the major problems associated with DILI in regards to the pharmaceutical industry, drug regulatory agencies, physicians and pharmacists, and patients. Expand
...
1
2
3
4
5
...